Company Quick10K Filing
Vycor Medical
Price0.14 EPS-0
Shares25 P/E-6
MCap3 P/FCF41
Net Debt-0 EBIT-1
TEV3 TEV/EBIT-6
TTM 2019-09-30, in MM, except price, ratios
10-Q 2020-09-30 Filed 2020-11-13
10-Q 2020-06-30 Filed 2020-08-17
10-Q 2020-03-31 Filed 2020-05-12
10-K 2019-12-31 Filed 2020-03-27
10-Q 2019-09-30 Filed 2019-11-12
10-Q 2019-06-30 Filed 2019-08-09
10-Q 2019-03-31 Filed 2019-05-13
10-K 2018-12-31 Filed 2019-03-29
10-Q 2018-09-30 Filed 2018-11-13
10-Q 2018-06-30 Filed 2018-08-10
10-Q 2018-03-31 Filed 2018-05-11
10-K 2017-12-31 Filed 2018-03-30
10-Q 2017-09-30 Filed 2017-11-13
10-Q 2017-06-30 Filed 2017-08-11
10-Q 2017-03-31 Filed 2017-05-11
10-K 2016-12-31 Filed 2017-03-31
10-Q 2016-09-30 Filed 2016-11-14
10-Q 2016-06-30 Filed 2016-08-09
10-Q 2016-03-31 Filed 2016-04-28
10-K 2015-12-31 Filed 2016-03-30
10-Q 2015-09-30 Filed 2015-11-13
10-Q 2015-06-30 Filed 2015-08-14
10-Q 2015-03-31 Filed 2015-05-15
10-K 2014-12-31 Filed 2015-03-31
10-Q 2014-09-30 Filed 2014-11-12
10-Q 2014-06-30 Filed 2014-08-12
10-Q 2014-03-31 Filed 2014-05-15
10-K 2013-12-31 Filed 2014-04-07
10-Q 2013-09-30 Filed 2013-11-15
10-Q 2013-06-30 Filed 2013-08-14
10-Q 2013-03-31 Filed 2013-05-15
10-K 2012-12-31 Filed 2013-04-01
10-Q 2012-09-30 Filed 2012-11-14
10-Q 2012-06-30 Filed 2012-08-14
10-Q 2012-03-31 Filed 2012-05-15
10-K 2011-12-31 Filed 2012-03-30
10-Q 2011-09-30 Filed 2011-11-14
10-Q 2011-06-30 Filed 2011-08-22
10-Q 2011-03-31 Filed 2011-05-13
10-K 2010-12-31 Filed 2011-03-31
10-Q 2010-09-30 Filed 2010-11-15
10-Q 2010-06-30 Filed 2010-08-16
10-Q 2010-03-31 Filed 2010-05-12
10-K 2009-12-31 Filed 2010-03-31
8-K 2020-06-30
8-K 2020-03-23
8-K 2019-03-29
8-K 2018-10-09
8-K 2018-03-30

VYCO 10Q Quarterly Report

Part I
Item 1.	Financial Statements
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item 4. Controls and Procedures
Part II
Item 1. Legal Proceedings
Item 1A. Risk Factors.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. Mine Safety Disclosures
Item 5. Other Information
EX-31.1 ex31-1.htm
EX-31.2 ex31-2.htm
EX-32.1 ex32-1.htm
EX-32.2 ex32-2.htm

Vycor Medical Earnings 2016-09-30

Balance SheetIncome StatementCash Flow
4.93.21.6-0.1-1.7-3.42012201420172020
Assets, Equity
0.50.1-0.2-0.6-0.9-1.32012201420172020
Rev, G Profit, Net Income
3.92.91.90.8-0.2-1.22012201420172020
Ops, Inv, Fin

10-Q 1 form10-q.htm

 

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

FORM 10-Q

 

(Mark One)

 

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal quarter ended September 30, 2016

 

[  ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

 

For the transition period from                     to                     

 

VYCOR MEDICAL, INC.

(Exact name of small business issuer as specified in its charter)

 

Delaware   333-149782   20-3369218
(State of Incorporation)  

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

6401 Congress Ave., Suite 140, Boca Raton, FL 33487
(Address of principal executive offices) (Zip code)

 

Issuer’s telephone number: (561) 558-2020

 

Securities registered under Section 12(g) of the Exchange Act:

Common Stock par value $0.0001

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [  ] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer [  ]   Accelerated Filer [  ]
     
Non-accelerated Filer [  ] (Do not check if a smaller reporting company)   Smaller Reporting Company [X]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [  ] Yes [  ] No

 

There were 11,220,856 shares outstanding of registrant’s common stock, par value $0.0001 per share, as of November 11, 2016.

 

Transitional Small Business Disclosure Format (check one): Yes [  ] No [X]

 

 

 

 
 

 

TABLE OF CONTENTS

 

PART I
Item 1. Financial Statements 3 
     
  Consolidated Balance Sheets as of September 30, 2016 (unaudited) and December 31, 2015 3
     
  Unaudited Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2016 and September 30, 2015. 4
     
  Unaudited Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and September 30, 2015. 5
     
  Notes to Unaudited Consolidated Financial Statements 6
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation 13
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 24
     
Item 4. Controls and Procedures 24
     
PART II
 
Item 1. Legal Proceedings 25
     
Item 1A. Risk Factors 25
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25
     
Item 3. Defaults Upon Senior Securities 25
     
Item 4. Mine Safety Disclosures 25
     
Item 5. Other Information 25
     
Item 6. Exhibits 25
     
SIGNATURES 26

 

 2 
 

 

PART I

 

ITEM 1. FINANCIAL STATEMENTS

 

VYCOR MEDICAL, INC.
Consolidated Balance Sheets

(unaudited)

 

    September 30, 2016     December 31, 2015  
ASSETS                
Current Assets                
Cash   $ 114,176     $ 347,477  
Trade accounts receivable, net of allowance for doubtful accounts of $2,711 and $2,711     116,849       106,340  
Inventory     223,111       292,538  
Prepaid expenses and other current assets     104,456       112,338  
Total Current Assets     558,592       858,693  
Fixed assets, net     417,711       521,105  
Intangible and Other assets:                
Trademarks     251,157       251,157  
Patents, net of accumulated amortization     256,539       323,138  
Website, net of accumulated amortization     16,105       19,548  
Security deposits     42,483       49,090  
Total Intangible and Other assets     566,284       642,933  
TOTAL ASSETS   $ 1,542,587     $ 2,022,731  
LIABILITIES AND STOCKHOLDERS’ EQUITY                
Current Liabilities                
Accounts payable   $ 195,787     $ 250,367  
Accrued interest: Related Party     5,909       .  
Accrued interest: Other     124,667       88,634  
Accrued liabilities     234,721       222,258  
Notes payable: Related Party     248,000       -  
Notes payable: Other     334,359       315,750  
Total Current Liabilities     1,143,443       877,009  
STOCKHOLDERS’ EQUITY                
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 270,307 and 252,336 issued and outstanding as at September 30, 2016 and December 31, 2015 respectively   $ 27     $ 25  
Common Stock, $0.0001 par value, 25,000,000 shares authorized at September 30, 2016 and December 31, 2015, 11,324,190 and 11,032,560 shares issued and 11,220,856 and 10,929,226 outstanding at September 30, 2016 and December 31, 2015 respectively     1,132       1,103  
Additional Paid-in Capital     24,948,423       24,346,057  
Treasury Stock (103,334 shares of Common Stock as at September 30, 2016 and December 31, 2015 respectively, at cost)     (1,033 )     (1,033 )
Accumulated Deficit     (24,677,087 )     (23,332,538 )
Accumulated Other Comprehensive Income     127,682       132,108  
Total Stockholders’ Equity     399,144       1,145,722  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 1,542,587     $ 2,022,731  

 

See accompanying notes to financial statements

 

 3 
 

 

VYCOR MEDICAL, INC.
Consolidated Statements of Comprehensive Loss
(unaudited)

 

    For the three months ended September 30,     For the nine months ended September 30,  
    2016     2015     2016     2015  
                         
Revenue   $ 325,777     $ 242,863     $ 1,105,269     $ 857,432  
Cost of Goods Sold     37,516       26,255       152,843       111,930  
Gross Profit     288,261       216,608       952,426       745,502  
                                 
Operating expenses:                                
Research and development     4,153       29,346       4,153       68,244  
Depreciation and Amortization     63,797       91,778       193,391       261,134  
General and administrative     535,535       604,655       1,876,382       1,991,726  
Total Operating expenses     603,485       725,779       2,073,926       2,321,104  
Operating loss     (315,224 )     (509,171 )     (1,121,500 )     (1,575,602 )
                                 
Other (expense) income                                
Interest expense: Other     (12,348 )     (11,934 )     (36,535 )     (35,616 )
Interest expense: Related Party     (4,663 )     -       (5,910 )     -  
Gain (loss) on foreign currency exchange     337       14,315       (877 )     (59,813 )
Change in fair value derivative liability     -       -       -       19,792  
Total Other (xpense) income     (16,674 )     2,381       (43,322 )     (75,637 )
                                 
Loss Before Credit for Income Taxes     (331,898 )     (506,790 )     (1,164,822 )     (1,651,239 )
Credit for income taxes     -       -       -       -  
Net Loss     (331,898 )     (506,790 )     (1,164,822 )     (1,651,239 )
Preferred stock dividends     (91,409 )     (85,331 )     (179,727 )     (167,777 )
Net Loss available to common shareholders     (423,307 )     (592,121 )     (1,344,549 )     (1,819,016 )
Comprehensive Loss                                
Net Loss     (331,898 )     (506,790 )     (1,164,822 )     (1,651,239 )
Foreign Currency Translation Adjustment     1,504       16,356       4,426       (64,222 )
Comprehensive Loss     (330,394 )     (490,434 )     (1,160,396 )     (1,715,461 )
                                 
Net Loss Per Share                                
Basic and diluted   $ (0.04 )   $ (0.05 )   $ (0.12 )   $ (0.17 )
                                 
Weighted Average Number of Shares Outstanding – Basic and Diluted     11,094,763       10,849,903       11,012,689       10,821,019  

 

See accompanying notes to financial statements

 

 4 
 

 

VYCOR MEDICAL, INC.
Consolidated Statement of Cash Flows
(unaudited)

 

   

For the nine months ended

September 30,

 
    2016     2015  
Cash flows from operating activities:                
Net loss     (1,164,822 )     (1,651,239 )
Adjustments to reconcile net loss to cash used in operating activities:                
Amortization of intangible assets     70,042       68,329  
Depreciation of fixed assets     130,646       200,995  
Inventory provision     7,631       12,632  
Share based compensation     422,671       214,607  
Loss on foreign exchange     877       59,813  
Unrealized gain on change in fair value of derivative liability     -       (19,792 )
                 
Changes in assets and liabilities:                
Accounts receivable     (10,509 )     11,051  
Inventory     61,796       52,349  
Prepaid expenses     91,269       21,456  
Accrued interest related party     5,910       -  
Accrued interest other     36,032       35,901  
Accounts payable     (54,580 )     (39,907 )
Accrued liabilities     10,756       (44,355 )
Security Deposit     6,607       4,078  
Cash used in operating activities     (385,674 )     (1,074,082 )
Cash flows from investing activities:                
Purchase of fixed assets     (28,264 )     (47,083 )
Purchase of website     -       (18,010 )
Acquisition of patents     -       (66,276 )
Cash used in investing activities     (28,264 )     (131,369 )
Cash flows from financing activities:                
Net proceeds from issuance of Notes Payable - Related Party     248,000       -  
Repayment of Notes Payable - Other     (64,466 )     (68,909 )
Cash provided by (used in) financing activities     183,534       (68,909 )
Effect of exchange rate changes on cash     (2,897 )     5,187  
Net decrease in cash     (233,301 )     (1,269,173 )
Cash at beginning of period     347,477       1,891,658  
Cash at end of period     114,176       622,485  
                 
Supplemental Disclosures of Cash Flow information:                
Non-Cash Transactions:                
Preferred stock dividends satisfied in new preferred stock   $ 179,727     $ 167,777  

 

See Accompanying Notes to Financial Statements

 

 5 
 

 

VYCOR MEDICAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2016
(unaudited)

 

1. BASIS OF PRESENTATION

 

The consolidated financial statements of the Company present the financial position, results of operations, and cash flows of Vycor Medical, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive financial statements have been omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2015 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

 

The consolidated financial statements for the three and nine months ended September 30, 2016 and 2015, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition and results of operations. The results of operations for the three and nine months ended September 30, 2016 and 2015 are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Certain prior period amounts have been reclassified to conform to the current presentation.

 

2. GOING CONCERN

 

The Company’s financial statements have been presented on a basis that contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and assumes the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $1,164,822 for the nine months ended September 30, 2016, and the Company expects to continue to incur additional losses in the future, including additional development costs, costs related to marketing and manufacturing expenses. The Company has incurred negative cash flows from operations since inception. As of September 30, 2016 the Company had a stockholders’ equity of $399,144 and $114,176 cash. The Company believes it would not have enough cash to meet its various cash needs unless the Company is able to obtain additional cash from the issuance of debt or equity securities. There is no assurance that additional funds from the issuance of equity will be available for the Company to finance its operations on acceptable terms or at all. If adequate funds are not available, the Company may have to delay development or commercialization of products or technologies that the Company would otherwise seek to commercialize, or cease some or all of its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

 

3. SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation and Basis of Presentation

 

The consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation. Certain reclassifications and format changes have been made to prior year amounts to conform to the current year presentation.

 

Recent Accounting Pronouncements

 

From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.

 

Net Loss Per Share

 

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.

 

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:

 

    September 30, 2016     December 31, 2015  
Stock options outstanding     705,557       25,557  
Warrants to purchase common stock     6,007,048       6,007,048  
Debentures convertible into common stock     235,926       215,908  
Preferred shares convertible into common stock     1,272,052       1,188,471  
Directors Deferred Compensation Plan     113,467       -  
Total     8,334,050       7,436,984  

 

 6 
 

 

4. NOTES PAYABLE

 

Related Party Notes Payable

 

As of September 30, 2016 and December 31, 2015 Related Party Notes Payable consists of:

 

    September 30, 2016     December 31, 2015  
In the period the Company issued promissory notes to Fountainhead Capital Management Limited for $248,000. The notes bear interest at 10% per annum and are payable on demand or by their one year anniversary.     248,000       -  
                 
Total Related Party Notes Payable     248,000       -  

 

Other Notes Payable

 

As of September 30, 2016 and December 31, 2015, Other Notes Payable consists of:

 

    September 30, 2016     December 31, 2015  
On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company an adjusted conversion price of $1.80 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended to December 31, 2016.     300,000       300,000  
                 
Insurance policy finance agreements. During the period ended September 30, 2016 the Company received new financing of 83,075 and made payments of $64,466. The notes are due over the next twelve months.     34,359       15,750  
                 
Total Other Notes Payable     334,359       315,750  

 

The company assesses the value of the beneficial conversion feature of its convertible debt by determining the intrinsic value of such conversion, under ASC 470, at the time of issuance. At the time of issuance of the convertible debt instruments set out above, the fair value of the stock was either the same or less than the conversion price, and so there was no value attributable to any beneficial conversion feature.

 

 7 
 

 

5. SEGMENT REPORTING, GEOGRAPHICAL INFORMATION

 

(a) Business segments

 

The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Set out below are the revenues, gross profits and total assets for each segment.

 

    Three Months Ended September 30,     Nine Months Ended September 30,  
    2016     2015     2016     2015  
Revenue:                                
Vycor Medical   $ 279,815     $ 182,889     $ 961,821     $ 662,996  
NovaVision   $ 45,962     $ 59,974     $ 143,448     $ 194,436  
    $ 325,777     $ 242,863     $ 1,105,269     $ 857,432  
Gross Profit                                
Vycor Medical   $ 245,412     $ 167,187     $ 820,830     $ 579,980  
NovaVision   $ 42,849     $ 49,421     $ 131,596     $ 165,522  
    $ 288,261     $ 216,608     $ 952,426     $ 745,502  

 

   

September 30,

2016

   

December 31,

2015

 
Total Assets:                
Vycor Medical   $ 828,322     $ 1,150,291  
NovaVision     714,265       872,440  
Total Assets   $ 1,542,587     $ 2,022,731  

 

(b) Geographic information

 

The Company operates in two geographic segments, the United States and Europe. Set out below are the revenues, gross profits and total assets for each segment.

 

    Three Months Ended September 30,     Nine Months Ended September 30,  
    2016     2015     2016     2015  
Revenue:                                
United States   $ 303,400     $ 205,674     $ 1,031,876     $ 737,671  
Europe   $ 22,377     $ 37,189     $ 73,393     $ 119,761  
    $ 325,777     $ 242,863     $ 1,105,269     $ 857,432  
Gross Profit                                
United States   $ 266,335     $ 185,521     $ 882,889     $ 641,847  
Europe   $ 21,926     $ 31,087     $ 69,537     $ 103,655  
    $ 288,261     $ 216,608     $ 952,426     $ 745,502  

 

   

September 30,

2016

   

December 31,

2015

 
Total Assets:                
United States   $ 1,288,204     $ 1,699,589  
Europe     254,383       323,142  
Total Assets   $ 1,542,587     $ 2,022,731  

 

 8 
 

 

6. EQUITY

 

Preferred Stock

 

During the nine months ended September 30, 2016, the Company paid an aggregate of 17,971 shares of Preferred D Stock, valued at $179,727, representing preferred stock dividends. The Preferred D shares are convertible on their terms at $2.15 per share of Common Stock into 83,586 shares. An aggregate of 17,142 shares of Preferred D Stock dividends were in respect of related parties (See Note 11).

 

Common Stock and Stock Grants

 

During January to September 2016, the Company granted 113,467 shares of Common Stock (valued at $57,000) to non-employee Directors. Under the terms of the Directors Deferred Compensation Plan, the receipt of these shares is deferred until the January 15th following the termination of their services as a director. As of September 30, 2016 these shares have yet to be issued.

 

During January to September 2016, the Company issued 54,657 shares of Common Stock (valued at $28,438) to members of the NovaVision, Inc. Scientific Advisory Board in respect of their services.

 

During January to September 2016, the Company issued 121,569 shares of Common Stock (valued at $90,000) to Fountainhead in accordance with the terms of a Consulting Agreement.

 

During April to September 2016, the Company issued 15,404 shares of Common Stock (valued at $8,334) to Techmed, Inc. in accordance with the terms of a consulting agreement.

 

During May to September 2016, the Company issued 100,000 share of Common Stock (valued at $40,700) to Valeo Consulting in accordance with the terms of a consulting agreement.

 

Warrants and Options

 

The details of the outstanding warrants and options are as follows:

 

          Weighted average  
STOCK WARRANTS:   Number of shares     exercise price per share  
Outstanding at December 31, 2014     5,911,715     $ 2.57  
Granted     100,000     $ 2.56  
Exercised     -       -  
Cancelled or expired     (4,667 )     -  
Outstanding at December 31, 2015     6,007,048     $ 2.57  
Granted     -       -  
Exercised     -       -  
Cancelled or expired     -       -  
Outstanding at September 30, 2016     6,007,048     $ 2.57  

 

 9 
 

 

          Weighted average  
STOCK OPTIONS:    Number of shares     exercise price per share  
Outstanding at December 31, 2014     5,557     $ 20.25  
Granted     20,000     $ 2.00  
Exercised     -       -  
Cancelled or expired     -       -  
Outstanding at December 31, 2015     25,557     $ 20.25  
Granted     680,000     $ 0.79  
Exercised     -       -  
Cancelled or expired     -       -  
Outstanding at September 30, 2016     705,557     $ 0.97  

 

As of September 30, 2016, the weighted-average remaining contractual life of outstanding warrants and options is 0.50 and 1.90 years, respectively.

 

7. SHARE-BASED COMPENSATION

 

Stock Option Plan

 

Under ASC Topic 718, the Company estimates the fair value of option awards on the date of grant using an option pricing model. The grant date fair value is recognized over the option vesting period, the period during which an employee is required to provide service in exchange for the award. No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Under these standards, compensation cost for employee cost for employee stock-based awards is based on the estimated grant-date fair value and recognized over the vesting period of the applicable award on a straight-line basis.

 

For the nine months ended September 30, 2016 and 2015, the Company recognized share-based compensation of $272,921 and $25,011, respectively, for employee stock options.

 

Stock appreciation rights may be granted either on a stand alone basis or in conjunction with all or part of any other stock options granted under the plan. As of September 30, 2016 there were no awards of any stock appreciation rights.

 

Non-Employee Stock Compensation

 

The Company from time to time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the “measurement date” using an option pricing model. The “measurement date” for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant.

 

Aggregate stock-based compensation expense charged to operations for stock and warrants granted to non-employees for the nine months ended September 30, 2016 was $149,750.

 

Stock-based Compensation Valuation Methodology

 

Stock-based compensation resulting from the issuance of Common Stock is calculated by reference to the valuation of the Stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. Expected volatility is based on the historical volatility of a peer group of publicly traded companies. The expected term of options and warrants was based upon the expected life of the option or warrant, and the risk-free rate is based on the U.S. Treasury Constant Maturity rate.

 

 10 
 

 

The following assumptions were used in calculations of the Black-Scholes option pricing model for the nine months ended September 30, 2016 and 2015:

 

    Nine Months Ended September 30,  
    2016     2015  
Risk-free interest rates     0.91 %     1.07 %
Expected life     1.5 years       3 years  
Expected dividends     0 %     0 %
Expected volatility     95 %     101 %
Vycor Common Stock fair value   $ 0.71     $ 2.00  

 

8. FAIR VALUE MEASUREMENTS

 

The Company has adopted ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period. The adoption of ASC 820 did not have an impact on the Company’s financial position or results of operations.

 

Under the terms of the Offering during the period January 2 to April 25, 2014, in five separate closings, a total of 2,397,631 Series A Warrants and Placement Agent Warrants were issued, which carried anti-dilution rights. Effective May 15, 2014 these anti-dilution rights were waived for all but 34,723 of the Series A Warrants and for all of the Placement Agent Warrants. The Company accounted for the Series A Warrants in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they had anti-dilution rights, they did not meet the criteria for equity treatment and needed to be recorded as a liability. Accordingly, the Company classified the warrant instrument as a liability at its fair value and adjusted the instrument to fair value at each reporting period. The anti-dilution provisions expired on June 11, 2015 and accordingly the liability was extinguished at that date.

 

The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis (the 34,723 Series A Warrants above) as of September 30, 2016 and December 31, 2015 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the liability, and includes situations where there is little, if any, market activity for the liability.

 

The table below provides a reconciliation of the beginning and ending balances for the liabilities measured using fair significant unobservable inputs (Level 3):

 

    Nine months ended September 30,  
    2016     2015  
Balance at start of period   $ -     $ 19,792  
                 
Change in fair value to June 11, 2015     -       485  
Extinguishment of liability June 11, 2015             (20,277 )
                 
Balance at end of period   $ -     $ -  

 

The fair value of the Series A Warrants was determined using a Monte Carlo Simulation. This model requires the input of highly subjective assumptions, including the expected price volatility, which is based on the historical volatility of a peer group of publicly traded companies. Changes in the subjective input assumptions can materially affect the estimate of fair value of the warrants and the Company’s results of operations could be impacted.

 

The following assumptions were used in calculations of the Monte Carlo Simulation model for the nine months ended September 30, 2016 and 2015:

 

    Nine Months Ended September 30,  
    2016     2015  
Risk-free interest rates     -       0.56-.73%  
Expected life     -       1.65 years  
Expected dividends     -       0 %
Expected volatility     -       90-93%  
Vycor Common Stock fair value     -       $1.59-1.84  

 

 11 
 

 

9. COMMITMENTS AND CONTINGENCIES

 

Lease

 

The Company leases approximately 10,000 sq. ft. located at 6401 Congress Ave., Suite 140, Boca Raton, FL 33487 from Catexor Limited Partnership for a gross rent of $15,439 plus sales tax per month. The term of the lease is 5 years and 6 months terminating July, 2017. The Company’s subsidiaries in Germany and the UK occupy properties on short term lease agreements. Rent expense for the nine months ended September 30, 2016 and 2015 was $159,176 and $150,000 respectively.

 

Potential German tax liability

 

In June 2012 the Company’s German subsidiary received a preliminary assessment for Magdeburg City trade tax of approximately €75,000 (approximately $85,000). This assessment is for the 2010 fiscal year and relates to the Company’s acquisition of the assets of the former NovaVision, Inc. An initial assessment for corporate tax for the same period has been preliminarily reduced to zero. The Company has not accepted this trade tax assessment and is in discussion with the relevant tax authorities with a view to its reduction. The tax authorities have agreed to suspend the assessment pending the outcome of certain court hearings, and the Company has agreed to make limited monthly payments on account. To the extent that this assessment (either a higher or a reduced amount) is ultimately confirmed by the tax authorities, the Company believes it has a very strong claim against certain professional advisors which would offset the liability in full. Accordingly, the Company has made no provision for this liability in the nine months ended September 30, 2016 and 2015 and the year ended December 31, 2015 respectively, other than recording the monthly payments as an expense.

 

Potential Patent Infringement

 

The Company was made aware in 2012 that a competitor had been granted a patent for related technology, and appeared to be entering the market with products that infringe the Company’s own issued patent. Following investigation, the Company initiated an invalidation of the competitor’s patent; in March 2014 the Patent Re-examination Board issued an Examination Decision invalidating all the claims of the competitor’s patent. The competitor appealed the decision, but the Company has contested the appeal. A final decision on the appeal is pending. The Company has, in the interim, also prepared to enforce its own patent against this competitor, however this competitor appears to have abandoned its product offering, making an enforcement action moot for the time being. The Company has also been made aware that a second competitor has filed a patent application for related technology and also may be producing a product that potentially infringes the Company’s patent, and has filed documents with the State Intellectual Property Office opposing grant of the patent application. As a general rule the Company intends to take all necessary action to protect its patent portfolio. As with all patent infringement actions, there is some risk that the accused infringer will not be found to infringe the claims, and an additional risk that the accused infringer will successfully challenge the validity of the asserted claims.

 

10. CONSULTING AND OTHER AGREEMENTS

 

The following agreements were entered into or remained in force during the nine months ended September 30, 2016:

 

Under the terms of an amended Consulting Agreement between the Company and Fountainhead, Fountainhead is paid a monthly retainer of $10,000 per month, payable $5,000 in cash and $5,000 payable in Company Common Stock at the end of each quarter based upon an agreed valuation formula. Effective September 2015, Fountainhead agreed to receive all of the fees in Common Stock.

 

In May 2016 the Company entered into a Consultancy agreement with Valeo Consulting LLC to assist in the raising of capital and related financial matters by dealing with potential investors, banks and brokers on behalf of the Company. Under the agreement the Company issued 50,000 shares of Vycor Common Stock on execution and 50,000 on August 1, 2016.

 

11. RELATED PARTY TRANSACTIONS

 

Peter Zachariou, director and David Cantor, director are investment managers of Fountainhead Capital Management which is a related party due to the size of its shareholding. Adrian Liddell, Chairman is a consultant for Fountainhead Capital Management.

 

During the period ended September 30, 2016, in accordance with the terms of the Consulting Agreement, the Company issued 121,569 shares of Common Stock (valued at $90,000) to Fountainhead.

 

During the nine months ended September 30, 2016, the Company paid an aggregate of 17,971 shares of Preferred D Stock, valued at $179,727, representing preferred stock dividends. The Preferred D shares are convertible on their terms at $2.15 per share of Common Stock into 83,586 shares. An aggregate of 17,142 shares of Preferred D Stock dividends were in respect of related parties.

 

During the period ended September 30, 2016, the Company issued unsecured loan notes to Fountainhead for a total of $248,000. The loan notes bear interest at a rate of 10% and are due on demand or by their one-year anniversary.

 

12. SUBSEQUENT EVENTS

 

The Company evaluated subsequent events through the date the financial statements were issued and filed with this Form 10Q:

 

None.

 

 12 
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Forward Looking Statements

 

This Interim Report on Form 10-Q contains, in addition to historical information, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PLSRA”), Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) regarding Vycor Medical, Inc. (the “Company” or “Vycor,” also referred to as “us”, “we” or “our”). Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Forward-looking statements involve risks and uncertainties. Forward-looking statements include statements regarding, among other things, (a) our projected sales, profitability, and cash flows, (b) our growth strategies, (c) anticipated trends in our industries, (d) our future financing plans and (e) our anticipated needs for working capital. They are generally identifiable by use of the words “may,” “will,” “should,” “anticipate,” “estimate,” “plans,” “potential,” “projects,” “continuing,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend” or the negative of these words or other variations on these words or comparable terminology. These statements may be found under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Description of Business,” as well as in this Form 10-Q generally. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results.

 

Any or all of our forward-looking statements in this report may turn out to be inaccurate. They can be affected by inaccurate assumptions we might make or by known or unknown risks or uncertainties. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially as a result of various factors, including, without limitation, the risks outlined under “Risk Factors” and matters described in this Form 10-Q generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur. You should not place undue reliance on these forward-looking statements. The forward-looking statements speak only as of the date on which they are made, and, except to the extent required by federal securities laws, we undertake no obligation to publicly update any forward-looking statements, whether as the result of new information, future events, or otherwise. We intend that all forward-looking statements be subject to the safe harbor provisions of the PSLRA.

 

1. Organizational History

 

The Company was formed as a limited liability company under the laws of the State of New York on June 17, 2005 as “Vycor Medical LLC”. On August 14, 2007, we converted into a Delaware corporation and changed our name to “Vycor Medical, Inc.”. The Company’s listing went effective on February 2009 and on November 29, 2010 Vycor completed the acquisition of substantially all of the assets of NovaVision, Inc. (“NovaVision”) and on January 4, 2012 Vycor, through its wholly-owned NovaVision subsidiary, completed the acquisition of all the shares of Sight Science Limited (“Sight Science”), a previous competitor to NovaVision.

 

2. Overview of Business

 

Vycor is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and operates two distinct business units within the medical device industry. Vycor Medical designs, develops and markets medical devices for use in neurosurgery. NovaVision provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Both businesses adopt a minimally or non-invasive approach. Both technologies have strong sales growth potential, address large potential markets and have the requisite regulatory approvals. The Company has 57 issued or allowed patents and a further 13 pending. The Company leverages joint resources across the divisions to operate in a cost-efficient manner.

 

The Company periodically engages in discussions with potential strategic partners for or purchasers of each or both of its operating divisions, and also gives consideration to a potential separation of the two entities into separately quoted entities.

 

 13 
 

 

Vycor Medical

 

Vycor Medical designs, develops and markets medical devices for use in neurosurgery. Vycor Medical’s ViewSite Brain Access System (“VBAS”) is a next generation retraction and access system that was fully commercialized in early 2010 and is the first significant technological change to brain tissue retraction in over 50 years in contrast to significant development in most other neuro-surgical technologies. Vycor Medical is ISO 13485:2003 compliant, and VBAS has U.S. FDA 510(k) clearance and CE Marking for Europe (Class III) for brain and spine surgeries, and regulatory approvals in Australia, Brazil, Canada, China, Korea, Japan, Russia and Taiwan.

 

 

 

We believe VBAS offers several advantages over other brain retractor systems, commonly known as ribbon or blade retractors that are metallic, including having the potential to significantly reduce brain tissue trauma that arises from excessive pressure at the edges of the blade. The design of VBAS can minimize the size of the brain entry access necessary for surgical procedures, and is believed to significantly reduce the pressure and hence trauma on the surrounding brain tissue.

 

NovaVision

 

NovaVision provides non-invasive, computer-based rehabilitation targeted at a substantial and largely un-addressed market of people who have lost their sight as a result of stroke or other brain injury. NovaVision addresses a significant target market, estimated at approximately $2 billion in each of the U.S. and the EU and over $13 billion globally.

 

NovaVision has a family of therapies that both restore and compensate for lost vision:

 

  Restoration of vision: NovaVision’s VRT and Sight Science’s Neuro-Eye Therapy (NeET), aim to improve visual sensitivity in a person’s blind area. VRT delivers a series of light stimuli along the border of the patient’s visual field loss. These programmed light sequences stimulate the border zone between the “seeing” and “blind” visual fields, repetitively challenging the visual cortex in the border zone with a large number of stimuli over the course of time. NeET targets deep within the blind area by repeated stimulation, allowing patients to detect objects within the blind field.
     
  Compensation and re-training: Normal eye movements are also affected after brain injury adding to the problems of blindness. NeuroEyeCoach provides a complementary therapy to VRT and NeET, which re-trains a patient to move their eyes, re-integrate left and right vision and to make the most of their remaining visual field.

 

VRT and NeuroEyeCoach are therefore highly complementary and are provided in an Internet-delivered suite to ensure broad benefits to NovaVision’s patients.

 

  

 

NovaVision also has models of VRT and NeuroEyeCoach for physicians and rehabilitation clinics, as well as VIDIT, a diagnostic program that enables therapists to perform high-resolution visual field tests in less than ten minutes.

 

NovaVision’s VRT is the only medical device aimed at the restoration of vision lost as a result of neurological damage which has FDA 510(k) clearance to be marketed in the U.S; and NeuroEyeCoach is registered in the US as a Class I 510(k) exempt device. VRT, NEC and NeET have CE Marking for the EU. NovaVision has 41 granted and 2 pending patents worldwide.

 

Competition

 

The VBAS device is both a brain access system and a retractor and is therefore unique with no direct competitors. Competitive manufacturers of brain retractors include Cardinal Health (V. Mueller line), Aesculap, Integra Life Science and Codman (Division of Johnson & Johnson). Nico Corporation has a brain access device specifically designed to work with its Myriad resection and suction product.

 

 14 
 

 

NovaVision provides restoration therapies (VRT and NeET) and compensation or saccadic therapies (NeuroEyeCoach) for those suffering vision loss as a result of neurological trauma. The other therapy type for this condition is substitution (optical aids such as prisms) and is not considered by NovaVision as competition.

 

In restoration, competition has been reduced through NovaVision’s acquisition of Sight Science and there are a few very small companies or entities offering some form of vision rehabilitation product in Germany. Within compensation there are no real direct competitors. Other companies in the general rehabilitation space include RevitalVision, PositScience and Dynavision. In the professional market, NovaVision competes with aggregator products or those that provide a range of non-specific therapies, such a Rehacom, Sanet Vision Integrator and Bioness BITS. NovaVision’s products are dedicated to vision.

 

The Market For the Company’s Products And Therapies

 

VBAS is used for craniotomy procedures. Based on statistics from the American Association of Neurological Surgeons (AANS), management estimates 700,000 such procedures are performed in the US annually. Of this, management believe approximately 225,000 (32 percent) are addressable by the VBAS range currently, with another 100,000 (total of 325,000 or 46 percent) addressable by an expanded future range. Management estimates, for the global market, there exists a current addressable market of approximately 1,100,000 procedures with another 500,000 addressable by an expanded VBAS range.

 

The market for NovaVision’s therapies comprises those suffering from vision loss resulting from neurological trauma such as stroke or other brain injury. The U.S. Centers for Disease Control (CDC) estimates there are approximately 8 million Americans who have previously had a stroke incident, with 795,000 additional strokes occurring annually; adjusting for repeat strokes and deaths, there are 481,000 new stroke survivors each year. Additionally, approximately 5.3 million Americans live with the long-term effects of a TBI, with 275,000 hospitalizations each year. The most recent scientific research estimates that approximately 28.5% experience some visual impediment and 20.5% of these patients experience a permanent visual field deficit, reducing mobility and other activities of daily living. The target market for VRT and NeET is this 20.5% subset of patients who have suffered a permanent visual field deficit; NeuroEyeCoach addresses all 28.5% of patients who experience visual impediments. Management estimates that the addressable target market for its therapies is approximately 2.9 million people in the US, approximately 2.8 million people in Europe and approximately 12.9 million people throughout the rest of the world.

 

Our Growth Strategy

 

Vycor Medical

 

Vycor Medical’s growth strategy includes:

 

1. Increasing U.S. market penetration through broader hospital coverage and targeted direct physician marketing. Vycor Medical’s sales and marketing strategy is to penetrate a well-defined target market of 4,500 neurosurgeons. Vycor markets direct to surgeons as well as marketing and distributing through independent distributors, with a focus both on adding new hospitals and expanding to additional surgeons in hospitals where VBAS is already approved, and to expand usage to a broader range of procedures. In order to expand its direct marketing and deepening its penetration, Vycor is exploring the creation of a Centers of Excellence medical education campaign and to that end has recently finalized new surgeon education and training materials including detailed videos produced with surgeons at Weill Cornell. Vycor is pursuing a policy of continually evaluating and upgrading its distributors as well as adding additional distributors in regions where it has little to no presence.

 

2. Provision of more Clinical and Scientific Data supporting the products superiority over the current standard-of-care blade retractors and to demonstrate VBAS’ potential for cost savings. Clinical and scientific data (in the form of peer reviewed articles, clinical studies and other reports and case studies) are critical in driving adoption, and in turn revenues, further and faster by demonstrating VBAS’ superiority as a minimally invasive access system which helps VBAS move further up the hospital cost/benefit curve. To date the Company has already had 10 Peer Reviewed studies and 4 other clinical papers and anticipates further studies to be published.

 

3. International Market Growth

 

Vycor Medical utilizes select medical device distributors with experience in neurosurgical devices in their countries or regions. VBAS has full regulatory approvals in Australia, Brazil, Canada, China, Europe (EU – Class III), Korea, Japan and Taiwan and is seeking or has partial regulatory approvals in India, Russia and Vietnam. Vycor Medical is actively pursuing new distribution agreements in the countries where it does not have any in place.

 

 15 
 

 

4. New Product Development

 

New Product Development is targeted at both driving the use of its existing VBAS product range through ancillary products and modalities that will facilitate the product’s use and through new product extensions to broaden VBAS applicability to procedures currently not addressed by the existing product line.

 

Vycor is modifying its existing VBAS product suite to make it more easy to integrate with Image Guidance Systems (IGS) by re-engineering VBAS so that the entire range of 12 devices, excluding the VBASmini, will be able to more easily accommodate pointers from all the main IGS manufacturers. Increasingly, all major neuro centers have image guidance systems, and where this is in place over 90% of surgeries are carried out using IGS and management strongly believes that the existing VBAS rigid structure lends itself well to being incorporated into this increasing trend.

 

NovaVision

 

While speech, physical, and occupational therapies are the long-standing treatment standards for stroke and TBI survivors, VRT is the first and only FDA-cleared clinical component of vision restoration to physically enhance the visual field after a stroke or brain injury. Increasingly the healthcare community, partly driven by strong lobbying by stroke associations worldwide, are recognizing that vision is not only a significant issue post stroke or brain injury, but that visual field loss can have a significant impact on the success of other rehabilitation modalities and the quality of life.

 

Our strategic vision for NovaVision has been to develop and provide a clinically supported, affordable and scalable visual therapy solution offering that provides broad benefits to those suffering visual impairment following neurological brain damage; and to offer solutions for both patients and physicians alike. Following a prolonged development program, aimed at broadening patient benefits, significantly reducing cost and making our therapies affordable and scalable, NovaVision was able to launch its Internet-delivered therapy suite in the US in June 2015 and in Europe in December 2015.

 

NovaVision has four routes-to-market aimed at patients and professionals, comprising: direct-to-patient; rehabilitation centers and clinics; stroke associations and support groups; and physicians. Given the company’s limited resources NovaVision is initially focusing on direct-to-patient, with a website lead-driven inbound and outbound marketing strategy targeted at prospective patients and relatives. Website metrics – particularly for the US and more recently Germany – are strong, showing good growth in traffic and rankings, and have been effective in generating leads. Our analysis of the campaign metrics in the US (including Google Ads) over the last 6 months have highlighted some key improvements that needed to be implemented which we are carrying out and which we believe could have a material impact on our lead generation.

 

Following the pilot launch of our NovaVision Center Model, comprising a vision diagnostics program and the NeuroEyeCoach training program, we have substantially broadened the delivery and licensing model in response to feedback from clinics. The new Center Model now has a complete suite for the professional market, including options for software download, CD Rom, Cloud based and Hardware delivery with flexible and cost-effective pricing options, and is now being offered in both the US and Europe.

 

Manufacturing

 

Vycor Medical uses a sub-contract manufacturer to manufacture, package, label and sterilize its VBAS products. The Company is in the process of migrating all its VBAS manufacturing to Life Science Outsourcing, Inc. in Brea, California that is FDA-registered and meets ISO standards and certifications.

 

Intellectual Property

 

Patents

 

Vycor Medical maintains a portfolio of patent protection on its methods and apparatus for its Brain and Spine products and technology in the form of issued patents and applications, both domestically and internationally, with a total of 16 granted/allowed and 11 pending patents.

 

 16 
 

 

NovaVision maintains a portfolio of patent protection on its methods and apparatus in the form of issued patents and applications, both domestically and internationally, with a total of 41 granted and 2 pending patents (including Sight Science).

 

NovaVision’s VRT is the only medical device aimed at the restoration of vision lost as a result of neurological damage which has FDA 510(k) clearance to be marketed in the U.S; and NeuroEyeCoach is registered in the US as a Class I 510(k) exempt device.

 

Trademarks

 

VYCOR MEDICAL is a registered trademark and VIEWSITE is a common law trademark.

 

NovaVision maintains a portfolio of registered trademarks for NOVAVISION, NOVAVISION VRT, VRT VISION RESTORATION THERAPY and NEUROEYECOACH, amongst others, along with relevant logos, both in the US and internationally.

 

Employees

 

We currently have 12 employees.

 

Comparison of the Three Months Ended September 30, 2016 to the Three Months Ended September 30, 2015

 

Revenue and Gross Margin:

 

    Three months ended  
    September 30,  
    2016     2015     % Change  
Revenue:                        
Vycor Medical   $ 279,815     $ 182,889       53 %
NovaVision   $ 45,962     $ 59,974       -23 %
    $ 325,777     $ 242,863       34 %
Gross Profit                        
Vycor Medical   $ 245,412     $ 167,187       47 %
NovaVision   $ 42,849     $ 49,421       -13 %
    $ 288,261     $ 216,608       33 %

 

Vycor Medical recorded revenue of $279,815 from the sale of its products for the three months ended September 30, 2016, an increase of $96,926, or 53%, over the same period in 2015. This reflected increased sales in the US and internationally. Gross margin of 88% was recorded for the three months ended September 30, 2016 compared to 91% for the same period in 2015.

 

NovaVision recorded revenues of $45,962 for the three months ended September 30, 2016, a decrease of $14,012 over the same period in 2015, and gross margin of 93%, compared to 82% for the same period in 2015. Revenue for the therapies is recognised over a 7 month period, and on a cash revenue basis the decline was $7,557, reflecting the growth in new patient starts during the period. The decrease was accounted for by Europe, where the Internet-delivered model was launched 6 months later than the U.S. Since the launch in the U.S., NovaVision has achieved a reduction in price to patients of 65%, from $2,500 for a six-month course of VRT alone to $900 for VRT and NeuroEyeCoach together. Given the price reduction, the company anticipated an initial decrease in revenues as volumes ramp up due to the new affordable and scalable therapy suite. New VRT/NeuroEyeCoach therapy suite patient starts in the U.S. for the three months ended September 30, 2016 increased by 9% over the same period in 2015, which was the first quarter of the Internet model. The Internet-delivered therapy suite was launched in Europe in December 2015, where similar price reductions have been achieved. New VRT/NeuroEyeCoach therapy suite patient starts in Europe for the three months ended September 30, 2016 increased by 44% over the same period in 2015.

 

 17 
 

 

Research and Development Expense:

 

Research and development (“R&D”) expenses were $4,153 for the three months ended September 30, 2016, as compared to $29,346 for the same period in 2015. Capitalized software development costs for the three months ended September 30, 2016 and 2015 were $0 and $6,357, respectively.

 

General and Administrative Expenses:

 

General and administrative expenses decreased by $69,120 to $535,535 for the three months ended September 30, 2016 from $604,655 for the same period in 2015. Included within General and Administrative Expenses are non-cash charges for share based compensation as the result of amortizing employee and non-employee shares, warrants and options which have been issued by the Company over various periods. The charge for the three months ended September 30, 2016 was $74,721, a decrease of $1,426 over $76,147 in 2015. Also included within General and Administrative Expenses are Sales Commissions, which increased by $15,518 to $48,508. The remaining General and Administrative expenses decreased by $83,212 from $495,518 to $412,306.

 

An analysis of the change in cash and non-cash G&A is shown in the table below:

 

    Cash G&A     Non-Cash G&A  
Other (travel/regulatory/premises)     (27,843 )     -  
Investor relations and road show costs     (25,018 )     (10,135 )
Sales, marketing and travel     (22,866 )     -  
Board, financial and scientific advisory     (20,925 )     8,709  
Legal, professional and other consulting     5,667       -  
Payroll     7,773       -  
Total change     (83,212 )     (1,426 )

 

Interest Expense:

 

Interest comprises expense on the Company’s debt and insurance policy financing. Related Party Interest expense for the three months ended September 30, 2016 increased by $4,663 to $4,663 from $0 for 2015. Other Interest expense for 2016 increased by $414 to $12,348 from $11,934 for 2015.

 

Comparison of the Nine Months Ended September 30, 2016 to the Nine Months Ended September 30, 2015

 

Revenue and Gross Margin:

 

    Nine months ended  
    September 30,  
    2016     2015     % Change  
Revenue:                        
Vycor Medical   $ 682,006     $ 480,107       45 %
NovaVision   $ 97,486     $ 134,463       -26 %
    $ 779,492     $ 614,570       29 %
Gross Profit                        
Vycor Medical   $ 575,420     $ 412,794       39 %
NovaVision   $ 88,747     $ 116,102       -24 %
    $ 664,167     $ 528,896       26 %

 

 18 
 

 

Vycor Medical recorded revenue of $961,821 from the sale of its products for the nine months ended September 30, 2016, an increase of $298,825, or 45%, over the same period in 2015. This reflected increased sales in the US and internationally. Gross margin of 85% was recorded for the three months ended September 30, 2016 compared to 87% for the same period in 2015; the difference in margin is mainly attributed to costs related to the migration to a new manufacturer and the manufacturing of the VBASMini.

 

NovaVision recorded revenues of $143,448 for the nine months ended September 30, 2016, a decrease of $50,988 over the same period in 2015, and gross margin of 92%, compared to 93% for the same period in 2015. The U.S. accounted for $9,861 of the decrease with the balance in Europe, where the Internet-delivered model was launched 6 months later than the U.S. Since the launch in the U.S., NovaVision has achieved a reduction in price to patients of 65%, from $2,500 for a six-month course of VRT alone to $900 for VRT and NeuroEyeCoach together. Given the price reduction, the company anticipated an initial decrease in revenues as volumes ramp up due to the new affordable and scalable therapy suite. New VRT/NeuroEyeCoach therapy suite patient starts in the US for the nine months ended September 30, 2016 increased by 41% over the same period in 2015. The Internet-delivered therapy suite was launched in Europe in December 2015, where similar price reductions have been achieved. New VRT/NeuroEyeCoach therapy suite patient starts in Europe for the nine months ended September 30, 2016 increased by 33% over the same period in 2015.

 

Research and Development Expense:

 

Research and development (“R&D”) expenses were $4,153 for the nine months ended September 30, 2016, as compared to $68,244 for the same period in 2015. Capitalized software development costs for the nine months ended September 30, 2016 and 2015 were $0 and $32,843, respectively.

 

General and Administrative Expenses:

 

General and administrative expenses decreased by $115,344 to $1,876,382 for the nine months ended September 30, 2016 from $1,991,726 for the same period in 2015. Included within General and Administrative Expenses are non-cash charges for share based compensation as the result of amortizing employee and non-employee shares, warrants and options which have been issued by the Company over various periods. The charge for the nine months ended September 30, 2016 was $422,671, an increase of $208,064 over $214,607 in 2015. Also included within General and Administrative Expenses are Sales Commissions, which increased by $24,406 to $142,615. The remaining General and Administrative expenses decreased by $347,814 from $1,658,912 to $1,311,097.

 

An analysis of the change in cash and non-cash G&A is shown in the table below:

 

    Cash G&A     Non-Cash G&A  
Investor relations and road show costs     (105,126 )     (20,460 )
Other (travel/regulatory/premises)     (94,393 )     -  
Board, financial and scientific advisory     (85,297 )     248,637  
Payroll     (63,714 )     (20,113 )
Sales and marketing     (15,981 )     -  
Legal, professional and other consulting     16,697       -  
Total change     (347,814 )     208,064  

 

 19 
 

 

Interest Expense:

 

Interest comprises expense on the Company’s debt and insurance policy financing. Interest expense for 2016 increased by $6,829 to $42,445 from $35,616 for 2015. The increase includes interest on Related Party of $5,910.

 

Interest comprises expense on the Company’s debt and insurance policy financing. Related Party Interest expense for the nine months ended September 30, 2016 increased by $5,910 to $5,910 from $0 for 2015. Other Interest expense for 2016 increased by $919 to $36,535 from $35,616 for 2015.

 

Liquidity and Capital Resources

 

Liquidity

 

The following table shows cash flow and liquidity data for the periods ended September 30, 2016 and December 31, 2015:

 

    September 30, 2016     December 31, 2015     $ Change  
Cash   $ 114,176     $ 347,477     $ (233,301 )
Accounts receivable, inventory and other current assets   $ 444,416     $ 511,216     $ (66,800 )
Total current liabilities   $ (1,143,443 )   $ (877,009 )   $ (266,434 )
Working capital   $ (584,850 )   $ (18,316 )   $ (566,534 )
Cash provided by (used in) financing activities   $ 183,534     $ (85,300 )   $ 268,834  

 

Operating Activities. Cash used in operating activities comprises net loss adjusted for non-cash items and the effect of changes in working capital and other activities. The net repayment of normal insurance financing should also be taken into account when considering cash used in operating activities.

 

The following table shows the principle components of cash used in operating activities during the nine months ended September 30, 2016 and 2015, with a commentary of changes during the periods and known or anticipated changes:

 

    September 30, 2016     September 30, 2015     $ Change  
Net loss   $ (1,164,822 )   $ (1,651,239 )   $ 486,417  
                         
Adjustments to reconcile net loss to cash used in operating activities:                        
Amortization and depreciation of assets   $ 200,688     $ 269,324     ($ (68,636 )
Share based compensation   $ 422,671     $ 214,607     $ 208,064  
Changes in value of derivative liability and gain or loss on foreign exchange   $ 877     $ 40,021     ($ (39,144 )
Other   $ 7,631     $ 12,632     ($ (5,001 )
    $ 631,867     $ 536,584     $ 95,283  
                         
Changes in working capital                        
Accounts receivable, accounts payable and accrued liabilities   $ (54,333 )   $ (73,211 )   $ 18,878  
Inventory   $ 61,796     $ 52,349     $ 9,447  
Prepaid expenses and net insurance financing repayments   $ 26,803     $ (47,453 )   $ 74,256  
Accrued interest (not paid in cash)   $ 41,942     $ 35,901     $ 6,041  
Other   $ 6,607     $ 4,078     $ 2,529  
    $ 82,815     $ (28,336 )   $ 111,151  
                         
Cash used in operating activities, adjusted for net insurance repayments   $ (450,140 )   $ (1,142,991 )   $ 692,851  

 

 20 
 

 

The adjustments to reconcile net loss to cash of $631,867 in the period have no impact on Liquidity. The net change in accounts receivable, accounts payable and accrued liabilities reflect the normal course of business and change between periods mainly as a result of larger than normal orders from customers or larger than normal expenditures. The net use of cash largely reflects the payment for inventory and other manufacturing costs in the fourth quarter of 2015 and first quarter of 2016 as part of Vycor’s ongoing manufacturing migration. Vycor’s normal inventory manufacturing purchasing cycle is to build up inventory in the fourth and first quarters; during the nine-month period the sale of purchased inventory was a net source of cash, this will reverse in the fourth quarter of 2016 and the first quarter of 2017 with inventory being purchased. Prepaid expenses and net insurance repayments were a source of cash during the period; this follows the normal pattern of cash flow for Vycor’s annual contractual obligations such as insurance policies and licenses. The impact on cash flow during the 2015 period was impacted by the booking of molds and other manufacturing costs related to the migration process to prepaids, before the molds were brought into service during the fourth quarter of 2015. Accrued interest represents interest due on the Company’s debt which, under its terms, is only paid out at final maturity.

 

Investing Activities. Cash used in investing activities for the nine months ended September 30, 2016 was $28,264, which reflected additional expenditure on molds for Vycor Medical and IT infrastructure. Vycor Medical is engaged in the final stage of migrating and consolidating it’s manufacturing and also making certain improvements to the molds for its VBAS product. This will entail significantly increased expenditure during the fourth quarter of 2016 and the first half of 2017, which will have an impact on liquidity and cash flow.

 

Financing Activities. During the period Vycor’s largest shareholder, Fountainhead, provided $248,000 of funding in the form of notes payable.

 

Liquidity and Plan of Operations

 

During the nine months ended September 30, 2016 we have reduced our Cash used in operations, adjusted for net insurance repayments, to $450,140 from $1,142,991 for the nine months ended September 30, 2015. Nonetheless, on this basis, average monthly operating cash usage is approximately $50,000 and the balance of cash at September 30, 2016 represents a little over two months of operating cash usage.

 

Fountainhead is currently providing working capital funding to the Company on an as-needed basis, although there is no formal commitment and no guarantee that this will continue to be the case. We are considering seeking additional equity or debt funding to support the continued operations of the Company.

 

As described earlier in this ITEM 2 “Our Growth Strategy”, the Company is executing on a plan to achieve a growth in revenues for both the Vycor Medical and NovaVision divisions, and thereby further reduce its cash operating usage. For Vycor Medical this includes in particular: increasing penetration in the US market through targeted marketing and a potential new medical education program; increased international market growth; and new product development centered around the modification of its VBAS product range to make it more easy to integrate with IGS systems. For NovaVision, after a prolonged and now complete period of re-development, the Company is focusing its resources on direct-to-patient marketing through a website lead-driven inbound and outbound marketing strategy. In addition, the Company is now starting to market its NovaVision Center Model to medical professionals, with a broad and flexible range of delivery and licensing options.

 

Going Concern

 

The Company’s financial statements have been presented on a basis that contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and assumes the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $1,164,822 for the nine months ended September 30, 2016, and the Company expects to continue to incur additional losses in the future, including additional development costs, costs related to marketing and manufacturing expenses. The Company has incurred negative cash flows from operations since inception. As of September 30, 2016 the Company had a stockholders’ equity of $399,144 and cash and cash equivalents of $114,176. The Company believes it would not have enough cash to meet its various cash needs unless the Company is able to obtain additional cash from the issuance of debt or equity securities. Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern in the medium to longer term. There is no assurance that additional funds from the issuance of equity will be available for the Company to finance its operations on acceptable terms or it all. If adequate funds are not available, the Company may have to delay development or commercialization of products or technologies that the Company would otherwise seek to commercialize, or cease some or all of its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

 

 21 
 

 

Critical Accounting Policies and Estimates

 

Uses of estimates in the preparation of financial statements

 

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimated. To the extent management’s estimates prove to be incorrect, financial results for future periods may be adversely affected. Significant estimates and assumptions contained in the accompanying consolidated financial statements include management’s estimate of the allowance for uncollectible accounts receivable, amortization of intangible assets, and the fair values of options and warrant included in the determination of debt discounts and share based compensation.

 

Research and Development

 

The Company expenses all research and development costs as incurred.

 

Cash and cash equivalents

 

The Company maintains cash balances at various financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250,000. Cash balances may at times exceed the FDIC insured limits. Cash also includes a US investment account in a money market backed by government securities up to 105% of the account balance. The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Included within cash are deposits paid by patients, held by the Company until the patient returns the VRT device or chinrest at the end of therapy. At September 30, 2016 and December 31, 2015 patient deposits amounted to $34,778 and $31,377, respectively, and are included in Accrued Liabilities.

 

Fixed assets

 

The Company records fixed assets at cost and calculates depreciation using the straight-line method over the estimated useful life of the assets, which is estimated to be between three and seven years. Maintenance, repairs and minor renewals are charged to expense when incurred. Replacements and major renewals are capitalized.

 

Derivative Liability

 

The Company accounted for the 34,723 Series A Warrants issued in connection with the 2014 Offering (all as defined in Note 8), the holders of which had not waived their anti-dilution rights (as detailed further in Note 8) in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they had anti-dilution rights, they did not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classified the warrant instrument as a liability at its fair value and adjusted the instrument to fair value at each reporting period. This liability was subject to re-measurement at each balance sheet date until exercised or until the anti-dilution provisions contained within the warrant agreements expired, and was classified in the balance sheet as a current liability. Any change in fair value of the warrant liability was recognized in the Company’s statement of operations as other income (loss). The anti-dilution provisions expired on June 11, 2015 and accordingly the liability has been extinguished.

 

Income taxes

 

We use the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

 22 
 

 

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have no material uncertain tax positions for any of the reporting periods presented.

 

Patents and Other Intangible Assets

 

The Company capitalizes legal and related costs associated with the establishment and enhancement of patents for its products once patents have been applied for. Costs associated with the development of the patented item or processes are charged to research and development costs as incurred. The capitalized costs are amortized over the life of the patent. The Company reviews intangible assets on an annual in accordance with the authoritative guidance. Trademarks have an indefinite life and are reviewed annually by management for impairment in accordance with the authoritative guidance.

 

Software Development Costs

 

The authoritative accounting guidance requires software development costs to be capitalized upon completion of the preliminary project stage. Accordingly, direct internal and external costs associated with the development of the features and functionality of the Company’s software, incurred during the application development stage, are capitalized and amortized using the straight-line method over the estimated life of five years.

 

Revenue Recognition

 

Vycor Medical generates revenue from the sale of its surgical access system to hospitals and other medical professionals. Vycor Medical records revenue when a completed contract for the sale exists, the product is invoiced and shipped to the customer. Vycor Medical does not provide for product returns or warranty costs.

 

NovaVision generates revenues from various programs, therapy services and other sources such as license sales. Therapy services revenues represent fees from NovaVision’s vision restoration therapy software, eye movement training software, diagnostic software, clinic set up and training fees, and the professional and support services associated with the therapy. NovaVision provides vision restoration therapy directly to patients. The typical vision restoration therapy consists of six modules, performed on average over 6 months. A patient contract comprises set-up fees and monthly therapy fees. Set-up fees are recognized at the outset of the contract and therapy revenue is recognized ratably over the therapy period. Patient therapy is restricted to being completed by a patient within a specified time frame. NovaVision’s saccadic training software is generally completed within 2-4 weeks and revenue is therefore recognized fully at commencement.

 

Deferred revenue results from patients paying for the therapy in advance of receiving the therapy.

 

Accounts Receivable and Allowance for Doubtful Accounts Receivable

 

The Company’s accounts receivable are due from the hospitals and distributors in the case of Vycor Medical, and from patients directly for therapy or physicians for diagnostic products in the case of NovaVision. Accounts receivable are due once products have been delivered or at the time the therapy is initiated; however, some NovaVision therapy patients make monthly payments during the therapy program. The outstanding balances are stated net of an allowance for doubtful accounts. The Company determines its allowance by considering a number of factors, including the length of time accounts receivable are past due, and the customer’s ability to pay its obligations. The Company writes off accounts receivable when they become uncollectible.

 

Inventory

 

Inventories are stated at the weighted average cost method. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose of the product. If the Company identifies excess, obsolete or unsalable items, its inventories are written down to their realizable value in the period in which the impairment is first identified. The provision for inventory for the years ended September 30, 2016 and 2015 was $7,631 and $12,632, respectively. Shipping and handling costs incurred for inventory purchases and product shipments are recorded in cost of sales.

 

 23 
 

 

Foreign Currency

 

The Euro is the local currency of the country in which NovaVision GmbH conducts its operations and is considered the functional currency of this entity; the GB Pound is the local currency of the country in which Sight Science Limited conducts its operations and is considered the functional currency of this entity. All balance sheet amounts are translated to U.S. dollars using the U.S. exchange rate at the balance sheet date except for the equity section which is translated at historical rates. Operating statement amounts are translated using an average exchange rate for the period of operations. Foreign currency translation effects are accumulated as part of the accumulated other comprehensive income (loss) and included in shareholders’ (deficit) in the accompanying Consolidated Balance Sheet.

 

Educational marketing and advertising expenses

 

The Company may incur costs for the education of customers on the uses and benefits of its products. The Company will include education, marketing and advertising expense as a component of selling, general and administrative costs as such costs are incurred.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable

 

ITEM 4. CONTROLS AND PROCEDURES

 

(a) Disclosure Controls and Procedures

 

We are required to maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer (also our principal executive officer) and our chief financial officer (also our principal financial and accounting officer) to allow for timely decisions regarding required disclosure.

 

The Company’s management, including our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”), have evaluated the effectiveness of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act), as of the end of the period covered by this report. Based on such evaluation, our CEO and our CFO have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective as of that date to provide reasonable assurance that the information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that information required to be disclosed by the Company in the reports its files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its CEO and its CFO, as appropriate, to allow timely decisions regarding required disclosure. There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

(b) Changes in Internal Controls

 

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) under the Exchange Act) during the fiscal period to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

The Company’s management, including the Company’s CEO and CFO, does not expect that the Company’s internal control over financial reporting will prevent all errors and all fraud. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate.

 

 24 
 

 

PART II

 

ITEM 1. LEGAL PROCEEDINGS

 

We are subject from time to time to litigation, claims and suits arising in the ordinary course of business. As of November 14, 2016, we were not a party to any material litigation, claim or suit whose outcome could have a material effect on our financial statements.

 

ITEM 1A. RISK FACTORS.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Name of Purchaser   Issue Date   Security   Shares     Consideration
ALVARO PASCUAL-LEONE M.D.   1/31/2016   Common     3,801     Consulting Fees
JOSEF ZIHL   1/31/2016   Common     4,223     Consulting Fees
FOUNTAINHEAD CAPITAL MANAGEMENT LIMITED   2/5/2016   Series D. Pref.     6,154     Series D Dividend
PETER C. ZACHARIOU   2/5/2016   Series D. Pref.     2,270     Series D Dividend
CRAIG KIRSCH   2/5/2016   Series D. Pref.     407     Series D Dividend
JASON BARTON   3/31/2016   Common     4,464     Consulting Fees
JOSE ROMANO   3/31/2016   Common     4,464     Consulting Fees
FOUNTAINHEAD CAPITAL MANAGEMENT LIMITED   3/31/2016   Common     16,667     Consulting Fees
TECHMED, INC.   4/2/2016   Common     9,921     Consulting Fees
ALVARO PASCUAL-LEONE M.D.   4/30/2016   Common     4,688     Consulting Fees
VALEO CONSULTING   5/6/2016   Common     50,000     Consulting Fees
JASON BARTON   6/30/2016   Common     5,307     Consulting Fees
JOSE ROMANO   6/30/2016   Common     5,307     Consulting Fees
FOUNTAINHEAD CAPITAL MANAGEMENT LIMITED   6/30/2016   Common     16,667     Consulting Fees
ALVARO PASCUAL-LEONE M.D.   7/31/2016   Common     5,859     Consulting Fees
VALEO CONSULTING   8/1/2016   Common     50,000     Consulting Fees
FOUNTAINHEAD CAPITAL MANAGEMENT LIMITED   8/5/2016   Series D. Pref.     6,369     Series D Dividend
PETER C. ZACHARIOU   8/5/2016   Series D. Pref.     2,349     Series D Dividend
CRAIG KIRSCH   8/5/2016   Series D. Pref.     421     Series D Dividend
TECHMED, INC.   9/1/2016   Common     5,483     Consulting Fees
JASON BARTON   9/30/2016   Common     8,272     Consulting Fees
JOSE ROMANO   9/30/2016   Common     8,272     Consulting Fees
FOUNTAINHEAD CAPITAL MANAGEMENT LIMITED   9/30/2016   Common     88,235     Consulting Fees
ALVARO PASCUAL-LEONE M.D.   10/31/2016   Common     7,212     Consulting Fees

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None

 

Index to Exhibits

 

Table insert nonbanded – table
 
31.1 Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 25 
 

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 14, 2016.

 

  Vycor Medical, Inc.
  (Registrant)
     
  By: /s/ Peter C. Zachariou
    Peter C. Zacharion
    Chief Executive Officer and Director (Principal Executive Officer)
  Date November 14, 2016
     
  By: /s/ Adrian Liddell
    Adrian Liddell
    Chairman of the Board and Director
    (Principal Financial and Accounting Officer)
  Date November 14, 2016

 

 26